drugset / Trial / NCT01254305
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
Timeline
- Start
- 2011-04
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Citalopram | Small molecule | 20 mg | Oral |
| Comparator | Citalopram | Small molecule | 40 mg | Oral |
| Comparator | Citalopram | Small molecule | 60 mg | Oral |
| Comparator | Fluoxetine | Small molecule | 20 mg | Oral |
| Comparator | Fluoxetine | Small molecule | 40 mg | Oral |
| Comparator | Fluoxetine | Small molecule | 60 mg | Oral |
| Subject | Levomilnacipran | Small molecule | 40 mg | Oral |
| Subject | Levomilnacipran | Small molecule | 120 mg | Oral |
| Comparator | Paroxetine | Small molecule | 20 mg | Oral |
| Comparator | Paroxetine | Small molecule | 40 mg | Oral |
| Comparator | Paroxetine | Small molecule | 60 mg | Oral |
| Comparator | Sertraline | Small molecule | 50 mg | Oral |
| Comparator | Sertraline | Small molecule | 100 mg | Oral |
| Comparator | Sertraline | Small molecule | 150 mg | Oral |